Kite Pharma

Allogeneic CAR-T biotechs fight to escape 'nuclear winter'

As autologous CAR-T continues to improve and Big Pharma pumps big cash into next-gen approaches, is there room left at the table for allogeneic CAR-T?

Darren Incorvaia Feb 11, 2026 11:00am

Gilead and Kites exhibit booth at ASH 2025

ASH: Anito-cel strengthens potential as Kite preps for launch

Dec 7, 2025 11:52am

Kite puts $1.64B on the line for Pregene's in vivo CAR-Ts

Oct 16, 2025 4:56pm

Gilead's Kite erodes $2.3B Shoreline cell therapy deal

Sep 3, 2025 3:18pm

Cell therapy biotech Appia shuts down as funding runs dry

Aug 25, 2025 5:55pm

Kite sails into in vivo CAR-T space via $350M Interius buyout

Aug 21, 2025 9:59am